Home > Publications database > The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics. > print

001     289187
005     20241029140424.0
024 7 _ |a 10.3390/pathogens13030184
|2 doi
024 7 _ |a pmid:38535528
|2 pmid
037 _ _ |a DKFZ-2024-00622
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Angelova, Assia Ludmilova
|0 P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0
|b 0
|e First author
|u dkfz
245 _ _ |a The Complex Role of Infectious Agents in Human Cutaneous T-Cell Lymphoma Pathogenesis: From Candidate Etiological Factors to Potential Therapeutics.
260 _ _ |a Basel
|c 2024
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711630465_21797
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:F230#LA:F230# / NEU #EA:D490#LA:D490#
520 _ _ |a Cutaneous T-cell lymphoma (CTCL) is a devastating, potentially fatal T-lymphocyte malignancy affecting the skin. Despite all efforts, the etiology of this disease remains unknown. Infectious agents have long been suspected as factors or co-factors in CTCL pathogenesis. This review deals with the panel of bacterial and viral pathogens that have been investigated so far in an attempt to establish a potential link between infection/carriage and CTCL development. A special focus is given to a recently discovered human protoparvovirus, namely the cutavirus (CutaV), which has emerged as a plausible CTCL etiological agent. Available evidence in support of this hypothesis as well as alternative interpretations and uncertainties raised by some conflicting data are discussed. The complexity and multifacetedness of the Parvoviridae family of viruses are illustrated by presenting another protoparvovirus, the rat H-1 parvovirus (H-1PV). H-1PV belongs to the same genus as the CutaV but carries considerable potential for therapeutic applications in cutaneous lymphoma.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a Parvoviridae
|2 Other
650 _ 7 |a cutaneous T-cell lymphoma
|2 Other
650 _ 7 |a cutavirus
|2 Other
650 _ 7 |a infectious etiology
|2 Other
650 _ 7 |a oncolytic H-1 parvovirus
|2 Other
700 1 _ |a Rommelaere, Jean
|0 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54
|b 1
|u dkfz
700 1 _ |a Ungerechts, Guy
|0 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191
|b 2
|e Last author
|u dkfz
773 _ _ |a 10.3390/pathogens13030184
|g Vol. 13, no. 3, p. 184 -
|0 PERI:(DE-600)2695572-6
|n 3
|p 184
|t Pathogens
|v 13
|y 2024
|x 2076-0817
856 4 _ |u https://inrepo02.dkfz.de/record/289187/files/pathogens-13-00184.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289187/files/pathogens-13-00184.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://inrepo02.dkfz.de/record/289187/files/jcm-13-02194-v2.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/289187/files/jcm-13-02194-v2.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:inrepo02.dkfz.de:289187
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)34bd069ab74ead9ac824c1e0896ecbf0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)2d7958ea507b0b738619074b38ec6d54
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2024
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PATHOGENS : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T15:01:22Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T15:01:22Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2023-04-12T15:01:22Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2023-04-12T15:01:22Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-10-26
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
920 2 _ |0 I:(DE-He78)F230-20160331
|k F230
|l KKE Virotherapie
|x 0
920 2 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 1
920 1 _ |0 I:(DE-He78)F230-20160331
|k F230
|l KKE Virotherapie
|x 0
920 1 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 1
920 0 _ |0 I:(DE-He78)F230-20160331
|k F230
|l KKE Virotherapie
|x 0
920 0 _ |0 I:(DE-He78)D490-20160331
|k D490
|l KKE Virotherapie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F230-20160331
980 _ _ |a I:(DE-He78)D490-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21